Verve Therapeutics Inc

VERV | $6.65 -0.15% 860K

(0.0% 1d) (-49.6% 1m) (-57.4% 1y) (0.0% 2d) (0.0% 3d) (-7.8% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 556,068,205
https://www.vervetx.com
Sec Filling | Patents | 63 employees

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

genetic cardiovascular

add to watch list Paper trade email alert is off

WM Technology Inc - Class A

MAPS 4 | $1.11 -2.63% -2.7% 290K

Information

(0.0% 1d) (20.9% 1m) (68.0% 1y) (0.0% 2d) (0.0% 3d) (-1.7% 7d) (-7.98% volume)
Earnings Calendar: 2024-04-16
Market Cap: $ 104,208,054
https://www.silverspikecap.com/sspk-spac
Sec Filling | Patents | 434 employees

(US) Silver Spike Acquisition Corp. (SSAC), an affiliate of Silver Spike Capital, is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The management team and board of directors are composed of veteran cannabis and finance industry executives and founders, including Scott Gordon, founder, and CEO of the Company, who began investing in the cannabis industry in 2014 and in 2016 co-founded and became Chairman of Egg Rock Holdings, the parent company of the Papa & Barkley family of cannabis products with related subsidiary assets in manufacturing, processing and logistics; and Dr. Orrin Devinsky, director of the Company, who is the director of the NYU Langone Comprehensive Epilepsy Center and is a Professor of Neurology, Neuroscience, Psychiatry, and Neuroscience at the NYU School of Medicine and who, since 2016 has served as the Chair of the Medical Advisory Board at Tilray, a pharmaceutical and cannabis company.

acquisitions cannabis blank check

add to watch list Paper trade email alert is off

Femasys Inc

FEMY | News | $1.33 1.53% 1.5% 160K

Manufacturing

(0.0% 1d) (-28.9% 1m) (48.8% 1y) (0.0% 2d) (-1.5% 3d) (-4.5% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 29,392,132

Sec Filling | Patents | 35 employees

our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t

contraception

add to watch list Paper trade email alert is off

ReShape Lifesciences Inc.

RSLS | $0.1707 3.93% 77K

Manufacturing

(0.0% 1d) (-7.0% 1m) (-94.4% 1y) (0.0% 2d) (0.0% 3d) (-2.7% 7d) (81.67% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 4,004,125
https://www.obalon.com
Sec Filling | Patents | 2 employees

(United States) Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

add to watch list Paper trade email alert is off

ATAI Life Sciences N.V.

ATAI | $1.85 -3.14% -3.24% 940K

Manufacturing

(0.0% 1d) (26.8% 1m) (-1.6% 1y) (0.0% 2d) (0.0% 3d) (4.1% 7d) (NaN% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 307,148,833
https://www.atai.life
Sec Filling | Patents | 35 employees

(DE) atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London.

treatment profitable msa

add to watch list Paper trade email alert is off